Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDCC Regulatory News (DCC)

Share Price Information for DCC (DCC)

Share Price is delayed by 15 minutes
Get Live Data
6,035.00    10.00 (0.17%)
Bid:
6,030.00
Ask:
6,035.00
Spread: 5.00 (0.083%)
Market Cap: £5.16b
DCC Live PriceLast checked at - London Stock Exchange

Intraday DCC Share Chart

Interim Management Statement

8 Feb 2023 07:00

RNS Number : 2284P
DCC PLC
08 February 2023
 
8 February 2023

 

DCC plc

 

Interim Management Statement

 

DCC reiterates guidance for strong profit growth; Q3 trading in line with expectations

 

DCC plc, the leading international sales, marketing and support services group, is issuing this Interim Management Statement for the third quarter ended 31 December 2022.

 

Third quarter ended 31 December 2022

Group operating profit for the third quarter ended 31 December 2022 was in line with expectations and ahead of the prior year, a good performance given the challenging macro environment.

 

DCC Energy delivered good operating profit growth in both the Mobility and Solutions businesses, notwithstanding the weather conditions being milder than average during the third quarter of the financial year. Operating profit declined in DCC Healthcare, where DCC Health & Beauty Solutions saw reduced demand as customers continued to reduce their inventory levels. This offset the strong growth delivered by DCC Vital, which performed well and benefited from the acquisition of MediGlobe. DCC Technology delivered good operating profit growth, in line with expectations, driven by strong growth in North America.

 

Year ending 31 March 2023

DCC continues to expect that the year ending 31 March 2023 will be another year of strong operating profit growth, in line with current market consensus expectations.

 

Development activity

DCC has now committed approximately £330 million to new acquisitions since the annual results announcement in May 2022. Since the Interim Results announcement in November 2022, DCC Energy has completed a number of small bolt-on acquisitions which provide solar and heat pump services to customers.

 

Year end results

DCC expects to announce its results for the year ending 31 March 2023 on 16 May 2023.

 

 

 

 

 

 

 

 

 

Investor enquiries:

Kevin Lucey, Chief Financial Officer

Tel: +353 1 2799 400

Rossa White, Head of Group Investor Relations

Email: investorrelations@dcc.ie

Media enquiries:

Powerscourt (Eavan Gannon/Genevieve Ryan)

Tel: +44 20 7250 1446

Email: DCC@powerscourt-group.com

 

 

About DCC plc

DCC is a leading international sales, marketing and support services group with a clear focus on sustainable growth. DCC is an ambitious and entrepreneurial business operating in 22 countries, supplying products and services used by millions of people every day. Building strong routes to market, driving for results, focusing on cash conversion and generating superior sustainable returns on capital employed enable the Group to reinvest in its business, creating value for its stakeholders.

Headquartered in Dublin, the Group operates across three sectors: energy, healthcare and technology, employing over 16,000 people. DCC plc is listed on the London Stock Exchange and is a constituent of the FTSE 100. In its financial year ended 31 March 2022, DCC generated revenue of £17.7 billion and operating profit of £589.2 million.

DCC has an excellent record, delivering compound annual growth of 14% in operating profit and generating an average return on capital employed of approximately 19% over 28 years as a public company.

Follow us on LinkedIn, Twitter.

www.dcc.ie

 

Forward-looking statements

This announcement contains some forward-looking statements that represent DCC's expectations for its business, based on current expectations about future events, which by their nature involve risk and uncertainty. DCC believes that its expectations and assumptions with respect to these forward-looking statements are reasonable, however because they involve risk and uncertainty as to future circumstances, which are in many cases beyond DCC's control, actual results or performance may differ materially from those expressed in or implied by such forward-looking statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTKDLFBXLLXBBK
Date   Source Headline
28th May 20206:21 pmRNSDirector/PDMR Shareholding
28th May 20201:02 pmRNSHolding in Company TR-1
19th May 20205:04 pmRNSBoard Changes
19th May 20207:00 amRNSResults for the year ended 31 March 2020
14th May 20203:30 pmRNSHolding in Company TR-1
27th Apr 20206:02 pmRNSDisclosure of Rights Attached to Equity Shares
16th Apr 20204:24 pmRNSDirector Declaration
9th Apr 20204:21 pmRNSHolding in Company TR-1
3rd Apr 20204:01 pmRNSHolding in Company TR-1
25th Mar 20203:22 pmRNSHolding in Company TR-1
25th Mar 20207:00 amRNSDCC Healthcare announces acquisition of Amerilab
19th Mar 20204:10 pmRNSHolding in Company TR-1
19th Mar 20209:46 amRNSHolding in Company TR-1
18th Mar 202012:14 pmRNSHolding in Company TR-1
6th Mar 20204:08 pmRNSHolding in Company TR-1
28th Feb 202010:54 amRNSTotal Voting Rights
24th Feb 20208:38 amRNSBoard Change
24th Feb 20208:34 amRNSChief Financial Officer Succession
12th Feb 20209:10 amRNSHolding in Company TR-1
4th Feb 20207:00 amRNSInterim Management Statement
17th Jan 20209:23 amRNSHolding in Company TR-1
3rd Jan 202010:03 amRNSHolding in Company - TR1
23rd Dec 201912:44 pmRNSHolding in Company TR-1
5th Dec 20195:44 pmRNSHolding in Company - TR1
29th Nov 20191:39 pmRNSTotal Voting Rights
27th Nov 20199:18 amRNSDirector Declaration
18th Nov 20196:14 pmRNSDirector/PDMR Shareholding
12th Nov 20197:00 amRNSResults for the six months ended 30 September 2019
12th Nov 20197:00 amRNSDCC Healthcare acquires Ion Laboratories
7th Nov 201911:30 amRNSHolding in Company TR-1
23rd Oct 20192:25 pmRNSHolding in Company TR-1
21st Oct 20195:01 pmRNSHolding in Company TR-1
18th Oct 20194:46 pmRNSHolding in Company TR-1
17th Oct 20199:43 amRNSHolding in Company TR-1
25th Sep 20195:39 pmRNSHolding in Company TR-1
4th Sep 20199:57 amRNSHolding in Company TR-1
9th Aug 201910:42 amRNSHolding in Company TR-1
7th Aug 20199:23 amRNSHolding in Company TR-1
31st Jul 20192:58 pmRNSTotal Voting Rights
16th Jul 20196:14 pmRNSDirector/PDMR Shareholding
12th Jul 20193:06 pmRNSResult of AGM
12th Jul 20197:00 amRNSInterim Management Statement
5th Jul 20199:06 amRNSHolding in Company TR-1
19th Jun 20199:22 amRNSHolding in Company TR-1
13th Jun 201911:37 amRNS2019 Annual Report, Notice of AGM and Proxy Form
31st May 20199:47 amRNSTotal Voting Rights
28th May 20197:00 amRNSHolding in Company TR-1
23rd May 20196:25 pmRNSDirector/PDMR Shareholding
22nd May 20199:43 amRNSHolding in Company TR-1
16th May 20199:03 amRNSHolding in Company TR-1

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.